Meneldor

What they do

Founded in 2016 by former executives of the global pharmaceutical company Synthon, Meneldor operates an evergreen syndicate model where investors pool capital through a Dutch Cooperative to invest directly in target companies. They focus exclusively on early-stage life sciences, specifically preclinical to Phase II biotech and pharma startups addressing significant unmet medical needs. The firm is highly distinctive for its rigorous scientific due diligence and deep operational expertise in drug development, manufacturing, and regulatory affairs. Additionally, Meneldor operates "The Meneldor Foundation," a philanthropic arm that uses the financial returns from a dedicated share class to support global biodiversity and nature conservation efforts.

What they look for

Meneldor focuses on early-stage biotech and pharma companies that (re)develop New Biological or Chemical Molecular Entities. They look for outstanding technology with strong intellectual property (IP), significant unmet medical needs, and attractive addressable markets. They actively scout for relatively low-risk and high-growth opportunities, requiring projects to be in the preclinical, Phase I, or Phase II stages with clear, well-defined clinical endpoints.

Stage

Pre-seed, Seed, Series A, Series B+

Sectors

Healthcare, Deeptech

Based

Druten, NL